NO940809D0 - Farmasöytisk preparat inneholdende en uricosurisk og en eksitatorisk aminosyre-antagonist - Google Patents

Farmasöytisk preparat inneholdende en uricosurisk og en eksitatorisk aminosyre-antagonist

Info

Publication number
NO940809D0
NO940809D0 NO940809A NO940809A NO940809D0 NO 940809 D0 NO940809 D0 NO 940809D0 NO 940809 A NO940809 A NO 940809A NO 940809 A NO940809 A NO 940809A NO 940809 D0 NO940809 D0 NO 940809D0
Authority
NO
Norway
Prior art keywords
amino acid
excitatory amino
uricosuric
acid antagonist
pharmaceutical preparation
Prior art date
Application number
NO940809A
Other languages
English (en)
Other versions
NO307645B1 (no
NO940809L (no
Inventor
Christopher Franklin Bigge
Jr Charles Price Taylor
Graham Johnson
Devin Franlin Welty
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO940809D0 publication Critical patent/NO940809D0/no
Publication of NO940809L publication Critical patent/NO940809L/no
Publication of NO307645B1 publication Critical patent/NO307645B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO940809A 1991-09-09 1994-03-08 Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat NO307645B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75640191A 1991-09-09 1991-09-09
PCT/US1992/007540 WO1993004688A1 (en) 1991-09-09 1992-09-02 Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist

Publications (3)

Publication Number Publication Date
NO940809D0 true NO940809D0 (no) 1994-03-08
NO940809L NO940809L (no) 1994-03-08
NO307645B1 NO307645B1 (no) 2000-05-08

Family

ID=25043303

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940809A NO307645B1 (no) 1991-09-09 1994-03-08 Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat

Country Status (16)

Country Link
US (4) US5407935A (no)
EP (1) EP0603301B1 (no)
JP (1) JP3218038B2 (no)
AT (1) ATE162075T1 (no)
AU (1) AU660717B2 (no)
CA (1) CA2115442C (no)
DE (1) DE69224069T2 (no)
DK (1) DK0603301T3 (no)
ES (1) ES2113957T3 (no)
GR (1) GR3026369T3 (no)
MX (1) MX9205127A (no)
NO (1) NO307645B1 (no)
NZ (1) NZ244243A (no)
PT (1) PT100850B (no)
WO (1) WO1993004688A1 (no)
ZA (1) ZA926837B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004688A1 (en) * 1991-09-09 1993-03-18 Warner-Lambert Company Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JP2002513380A (ja) 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
WO1998003541A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP1082113A2 (en) * 1998-05-26 2001-03-14 Peter Louis Carlen Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
CA2413201A1 (en) 2000-06-28 2002-01-03 Merck & Co., Inc. Treatment for cardiovascular disease
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
CA2609972C (en) * 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
US8461223B2 (en) 2005-04-07 2013-06-11 Aspen Aerogels, Inc. Microporous polycyclopentadiene-based aerogels
ITFI20050083A1 (it) * 2005-04-29 2006-10-30 Univ Firenze Uso dell'acido chinurenico per la prevenzione e il trattamento dello shock
US8841333B2 (en) 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
WO2007140293A2 (en) 2006-05-25 2007-12-06 Aspen Aerogels, Inc. Aerogel compositions with enhanced performance
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
EP2613780B1 (en) 2010-09-10 2014-11-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
US10583103B2 (en) 2013-03-13 2020-03-10 University Of Cincinnati Method of treating heart failure with preserved ejection fraction with probenecid
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
EP3427729A1 (en) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812458A (en) * 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
ES2069921T3 (es) * 1991-02-28 1995-05-16 Merrell Dow Pharma Antagonistas del nmda.
WO1993004688A1 (en) * 1991-09-09 1993-03-18 Warner-Lambert Company Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist

Also Published As

Publication number Publication date
EP0603301A1 (en) 1994-06-29
MX9205127A (es) 1993-07-01
DK0603301T3 (da) 1998-09-14
CA2115442A1 (en) 1993-03-18
US5627168A (en) 1997-05-06
CA2115442C (en) 2003-09-23
US5407935A (en) 1995-04-18
NO307645B1 (no) 2000-05-08
PT100850A (pt) 1993-10-29
EP0603301B1 (en) 1998-01-14
JP3218038B2 (ja) 2001-10-15
DE69224069T2 (de) 1998-07-02
PT100850B (pt) 1999-07-30
ZA926837B (en) 1994-03-08
US5942513A (en) 1999-08-24
AU2594392A (en) 1993-04-05
NO940809L (no) 1994-03-08
GR3026369T3 (en) 1998-06-30
ATE162075T1 (de) 1998-01-15
WO1993004688A1 (en) 1993-03-18
ES2113957T3 (es) 1998-05-16
AU660717B2 (en) 1995-07-06
DE69224069D1 (de) 1998-02-19
US5767119A (en) 1998-06-16
JPH06510544A (ja) 1994-11-24
NZ244243A (en) 1995-07-26

Similar Documents

Publication Publication Date Title
NO940809L (no) Farmasöytisk preparat inneholdende en uricosurisk og en eksitatorisk aminosyre-antagonist
PT705100E (pt) Guanidinas substituidas terapeuticas
DE69200685D1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
FI20000516A (fi) Bis-indolyylimaleimidijohdannaiset ja niiden valmistus
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
NO302366B1 (no) 4-merkaptoacetylamino-£2|benzazepinon(3)-derivater, og farmasöytisk preparat
FI941826A (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
IT1231942B (it) Derivato di piperazina o suo sale, procedimento per produrlo e composizione farmaceutica che lo contiene come ingrediente attivo
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE171935T1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
FI953899A (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
NO891703L (no) Farmasoeytiske sammensetninger for behandling av psoriasis.
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.
EA199800575A1 (ru) Производные пиперазина
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia
DK8893D0 (da) Medicament for treatment or prevention of disease

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees